<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Improved outcome after <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> surgery requires identification of novel risk factors of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> recurrence in order to personalise therapy, that is, enhanced selection of high-risk patients to additional radiochemotherapy or intensified follow-up </plain></SENT>
<SENT sid="1" pm="."><plain>In several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, high expression of the membrane-cytoskeleton linker ezrin has been suggested to impair prognosis but has not yet reached clinical application </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the expression of ezrin in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> with a focus on the identification of a marker for local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> recurrence </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Immunohistochemical expression of ezrin was analysed in 104 primary <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> from patients who developed local recurrences despite being treated with R0 major abdominal surgery </plain></SENT>
<SENT sid="4" pm="."><plain>Time to local recurrence and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> as well as 5-year overall and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival were used as end points </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ezrin expression was weak in 17% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, moderate in 62%, and intense in 21% </plain></SENT>
<SENT sid="6" pm="."><plain>The time to local recurrence was significantly shorter (p = 0.0004) for patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> showing high ezrin expression </plain></SENT>
<SENT sid="7" pm="."><plain>No correlation between ezrin expression and time to distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> was identified </plain></SENT>
<SENT sid="8" pm="."><plain>Survival data were similar between groups irrespective of ezrin expression in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Our findings suggest that increased expression of ezrin may represent a marker of aggressive biological behaviour in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Although further validation is needed, ezrin may represent a relevant marker for personalised treatment of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> with respect to risk of local recurrence after R0 surgery </plain></SENT>
</text></document>